Here, we used pwCF-derived nasal organoids obtained through the CRC approach from 38 different pwCF with CFTR genotypes eligible (FDA+) or non-eligible (FDA−) for FDA-approved modulators and tested their basal/residual or modulator-restored CFTR activity in vitro. The gene discussed is CFTR; the disease is colorectal carcinoma.